Clinical Trial Shows Repurposed Drug Relacorilant May Extend Survival in Aggressive Ovarian Cancer
A clinical trial has revealed that relacorilant, a drug originally used to treat Cushing's syndrome, may extend the lives of patients with platinum-resistant ovarian cancer. This form of cancer progresses within six months of starting platinum-based chemotherapy, which typically results in a survival expectancy of only one year post-diagnosis. The study, published in the Lancet, involved 381 patients who received either usual treatment or relacorilant. Results showed a 35% reduction in the risk of death among those treated with relacorilant, with an average survival extension of four months compared to the control group. Additionally, a separate study found that patients treated with pembrolizumab alongside usual care lived for an average of 17.7 months, compared to 14 months for those receiving usual care alone. Both drugs have been approved by the FDA for treating platinum-resistant ovarian cancer. 
